-
admin
Posts
CRISPR and Cas Gene Global Research Report 2024 | Now Available
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) — The “CRISPR and Cas Gene Global Market Report 2024” report has been added to ResearchAndMarkets.com’s offering. The crispr...
Axalta Releases Second Quarter 2024 Results
PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) — Axalta Coating Systems Ltd. (NYSE: AXTA) (“Axalta”), a leading global coatings company, announced its financial results for the...
Innovations In Employee Communications Conference: Powerful, New Internal Communications Strategies to Improve Workforce And Drive Results (Chicago, US – Sept 17-19, 2024 – In-Person/Online Options)
Dublin, Aug. 01, 2024 (GLOBE NEWSWIRE) — The “3rd Annual Innovations In Employee Communications: Powerful, New Internal Communications Strategies To Engage And Connect Your Workforce...
DiamiR Biosciences Secures EU Patent Covering the Use of microRNA Biomarkers from Bodily Fluids for Differential Diagnosis of Amyotrophic Lateral Sclerosis
NEW HAVEN, CT, and MONMOUTH JUNCTION, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) — DiamiR, a developer of innovative blood-based diagnostic tests for brain health and...
COUR Pharmaceuticals Announces Leadership Transition for Strategic Growth Objectives
Founder John J. Puisis to transition CEO role to current COO Dannielle Appelhans Mr. Puisis to remain on COUR Board of Directors CHICAGO, Aug. 01,...
Non-invasive Vagus Nerve Stimulation (nVNS) is effective at accelerating foreign language learning
Clinical Trial demonstrates that nVNS is an effective learning acceleration tool while simultaneously improving focus and decreasing fatigue in study participants ROCKAWAY, N.J., Aug. 01,...
Galectin Therapeutics Appoints Khurram Jamil, M.D. to Chief Medical Officer
NORCROSS, Ga., Aug. 01, 2024 (GLOBE NEWSWIRE) — Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced the...
Spinogenix Announces Open Enrollment for Phase 2 Study Evaluating SPG302 for the Treatment of Alzheimer’s Disease
SPG302 is a once-a-day pill with the potential to regenerate synapses to reverse declines in cognitive function in people with Alzheimer’s disease LOS ANGELES, Aug....
Frost & Sullivan Institute Commends Visionary Companies with the 2024 Enlightened Growth Leadership Best Practices Recognition for Commitment to Sustainability and Growth Excellence
SANTA CLARA, Calif., Aug. 1, 2024 /PRNewswire/ — The Frost & Sullivan Institute is excited to unveil the 2024 Enlightened Leadership Best Practices Recognition winners...
Mega Matrix announced that “Misplaced Love”: Misaligned Emotions and the Serendipities of True Love, was first released on July 31!
PALO ALTO, Calif., Aug. 1, 2024 /PRNewswire/ — Mega Matrix Corp. (“MPU” or the “Company”) (NYSE American: MPU), today announced that it launched its highly...